JP7372253B2 - 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ - Google Patents

癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ Download PDF

Info

Publication number
JP7372253B2
JP7372253B2 JP2020551269A JP2020551269A JP7372253B2 JP 7372253 B2 JP7372253 B2 JP 7372253B2 JP 2020551269 A JP2020551269 A JP 2020551269A JP 2020551269 A JP2020551269 A JP 2020551269A JP 7372253 B2 JP7372253 B2 JP 7372253B2
Authority
JP
Japan
Prior art keywords
cancer
indol
methyl
pyrimidine
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020551269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519262A5 (enExample
JP2021519262A (ja
Inventor
ヘーグベリ，マリタ
レンマーク，ステファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVIGA RESEARCH AB
Original Assignee
NOVIGA RESEARCH AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOVIGA RESEARCH AB filed Critical NOVIGA RESEARCH AB
Publication of JP2021519262A publication Critical patent/JP2021519262A/ja
Publication of JP2021519262A5 publication Critical patent/JP2021519262A5/ja
Application granted granted Critical
Publication of JP7372253B2 publication Critical patent/JP7372253B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020551269A 2018-04-05 2019-04-04 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ Active JP7372253B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1850380 2018-04-05
SE1850380-5 2018-04-05
PCT/SE2019/050312 WO2019194738A1 (en) 2018-04-05 2019-04-04 Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2021519262A JP2021519262A (ja) 2021-08-10
JP2021519262A5 JP2021519262A5 (enExample) 2022-04-07
JP7372253B2 true JP7372253B2 (ja) 2023-10-31

Family

ID=68101552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551269A Active JP7372253B2 (ja) 2018-04-05 2019-04-04 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ

Country Status (6)

Country Link
US (1) US11590130B2 (enExample)
EP (1) EP3773592B1 (enExample)
JP (1) JP7372253B2 (enExample)
CN (1) CN111936143A (enExample)
CA (1) CA3095709A1 (enExample)
WO (1) WO2019194738A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
JP2023524530A (ja) * 2020-05-04 2023-06-12 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN121127241A (zh) * 2023-03-10 2025-12-12 万春药业公司 肿瘤联合治疗及使用方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515450A (ja) 2008-03-27 2011-05-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン
JP2013500989A (ja) 2009-07-30 2013-01-10 武田薬品工業株式会社 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
JP2014508795A (ja) 2011-03-24 2014-04-10 ケミリア・エービー 新規のピリミジン誘導体
JP2014516989A (ja) 2011-05-31 2014-07-17 ニューゲン セラピューティクス， インコーポレイテッド ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤
US20170209594A1 (en) 2015-06-25 2017-07-27 Immunomedics, Inc. Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or parp inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976515A2 (en) 2006-01-17 2008-10-08 Abbott Laboratories Combination therapy with parp inhibitors
US20100249112A1 (en) 2007-05-25 2010-09-30 Astrazeneca R&D Combination of chk and parp inhibitors for the treatment of cancers
EP2217244A4 (en) 2007-11-12 2011-08-31 Bipar Sciences Inc TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES
RU2010128107A (ru) 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
ES2367760T3 (es) 2008-03-27 2011-11-08 Janssen Pharmaceutica, N.V. Derivados de quinazolinona como inhibidores de la polimerización de la tubulina.
CN102307475A (zh) 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌
EP2576514A1 (en) * 2010-06-04 2013-04-10 Exonhit Sa Substituted isoquinolines and their use as tubulin polymerization inhibitors
US9132120B1 (en) 2012-04-02 2015-09-15 Stc.Unm Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers
JP6615746B2 (ja) 2013-04-09 2019-12-04 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 腫瘍選択的併用療法
WO2017013593A1 (en) 2015-07-22 2017-01-26 Lupin Limited Isoquinolinone derivatives as parp inhibitors
EP3380454A4 (en) 2015-11-20 2019-04-03 Lee, Hoyun CHINOLINE-CHALCON COMPOUNDS AND USES THEREOF
WO2017223516A1 (en) 2016-06-24 2017-12-28 The Regents Of The University Of California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515450A (ja) 2008-03-27 2011-05-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン
JP2013500989A (ja) 2009-07-30 2013-01-10 武田薬品工業株式会社 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
JP2014508795A (ja) 2011-03-24 2014-04-10 ケミリア・エービー 新規のピリミジン誘導体
JP2014516989A (ja) 2011-05-31 2014-07-17 ニューゲン セラピューティクス， インコーポレイテッド ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤
US20170209594A1 (en) 2015-06-25 2017-07-27 Immunomedics, Inc. Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or parp inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clin. Cancer Res.，2010年，Vol.16, No.23，pp.5892-5899

Also Published As

Publication number Publication date
CN111936143A (zh) 2020-11-13
CA3095709A1 (en) 2019-10-10
US20210052583A1 (en) 2021-02-25
EP3773592A4 (en) 2022-02-23
WO2019194738A1 (en) 2019-10-10
EP3773592A1 (en) 2021-02-17
JP2021519262A (ja) 2021-08-10
EP3773592B1 (en) 2025-09-10
US11590130B2 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
JP7372253B2 (ja) 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ
US12310968B2 (en) Chiral diaryl macrocycles and uses thereof
JP6066421B2 (ja) 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法
CN115768427A (zh) 癌症疗法中用于靶向降解不可靶向的kras的新型小分子
US11666574B2 (en) Combination therapy involving diaryl macrocyclic compounds
CN107530336B (zh) 组合使用mdm2抑制剂和btk抑制剂的治疗方法
CN106132412A (zh) 治疗癌症的新方法
CA2944255A1 (en) New derivatives of cephalosporin for treating cancer
CA3174455A1 (en) Therapeutic uses of macrocyclic compounds
EP4495121A1 (en) Camptothecin derivatives that bind to ddx5 protein and prodrugs thereof
WO2022006292A1 (en) Nek2 proteolysis targeting chimeras for use in malignant disease
EP3324970A1 (en) Chlorobenzene substituted azaaryl compounds
Abe et al. 356 characterization of TAS-117, a novel, highly potent and selective inhibitor of AKT
EP3804721A1 (en) Antitumor agent and method for tumor therapy
JP2014091711A (ja) Ｈｓｐ９０阻害剤と抗腫瘍性白金錯体との組み合わせ
HK1233924B (en) Derivatives of cephalosporin for treating cancer
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer
JP2014034533A (ja) Ｈｓｐ９０阻害剤とｅｇｆｒチロシンキナーゼ阻害剤の組み合わせ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230621

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230921

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231019

R150 Certificate of patent or registration of utility model

Ref document number: 7372253

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150